AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ULTRAGENYX PHARMACEUTICAL · Biopharma company

Filing Registration

2nd Quarter (Apr 1 - June 30) 2025 · California · posted May 24, 2025

Lobbying activity 1

Health Issues

Rare & ultra-rare disease policy issues, newborn screening, genomic sequencing

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem